Mylan's Fulphila Approval: Lack Of US FDA AdComm May Be A Positive For Biosimilar Industry

 
• By Sue Sutter and Anju Ghangurde
  
Cubes
THE US FDA DECIDED AGAINST THE NEED FOR AN ADCOMM FOR FULPHILA
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics